Chembio to Host Conference Call to Discuss 2016 Financial Results
February 27 2017 - 8:50AM
Chembio Diagnostics, Inc. (NASDAQ:CEMI), which develops,
manufactures, markets and licenses point-of-care diagnostic tests,
announced today that it will report financial results for 2016
on March 7, 2017 after market close. John J. Sperzel,
Chembio's President and Chief Executive Officer, and Richard
Larkin, Chembio’s Chief Financial Officer will host a conference
call and webcast at 4:30 p.m. ET to discuss the financial
results for 2016 and review recent corporate developments. The
Company’s 10-K and earnings press release will be available after
4:00 p.m. ET on Chembio’s web site.
To participate on the conference call, please
dial (877) 407-0778 from the U.S. or (201) 689-8566 from outside
the U.S. To listen live via the Internet, please visit the
Investor Relations section of Chembio's website at
www.chembio.com.
To listen to a replay of the call, which will be
accessible until March 14, 2017 at 11:59 p.m. ET, please dial (877)
481-4010 from the U.S. or (919) 882-2331 from outside the U.S., and
enter conference ID #:10255. An archive of the webcast will
be available for 90 days on the Company's website at
www.chembio.com.
About Chembio Diagnostics
Chembio Diagnostics, Inc. develops,
manufactures, licenses and markets proprietary rapid diagnostic
tests in the growing $8.0 billion point-of-care testing
market. Chembio markets each of its DPP® HIV 1/2 Assay, HIV
1/2 STAT-PAK® Assay, and SURE CHECK® HIV 1/2 Assay, with these
Chembio brand names, in the U.S. and internationally both directly
and through third-party distributors. The Company's SURE CHECK® HIV
1/2 Assay previously has been exclusively sold in the U.S. as
Clearview® Complete HIV 1/2 Assay.
Chembio has developed a patented point-of-care
test platform technology, the Dual Path Platform (DPP®) technology,
which has significant advantages over lateral-flow technologies.
This technology is providing Chembio with a significant pipeline of
business opportunities for the development and manufacture of new
products.
Headquartered in Medford, NY, Chembio is
licensed by the U.S. Food and Drug Administration (FDA) as well as
the U.S. Department of Agriculture (USDA), and is certified for the
global market under the International Standards Organization (ISO)
directive 13485. Chembio Diagnostic Systems, Inc. is a wholly-owned
subsidiary of Chembio Diagnostics, Inc. For more information,
please visit: www.chembio.com.
Forward-Looking Statements
Statements contained herein that are not
historical facts may be forward-looking statements within the
meaning of the Securities Act of 1933, as amended.
Forward-looking statements include statements regarding the intent,
belief or current expectations of the Company and its
management. Such statements, which are estimates only,
reflect management's current views, are based on certain
assumptions, and involve risks and uncertainties. Actual
results, events, or performance may differ materially from the
above forward-looking statements due to a number of important
factors, and will be dependent upon a variety of factors,
including, but not limited to Chembio's ability to obtain
additional financing and to obtain regulatory approvals in a timely
manner, as well as the demand for Chembio's products. Chembio
undertakes no obligation to publicly update these forward-looking
statements to reflect events or circumstances that occur after the
date hereof or to reflect any change in Chembio's expectations with
regard to these forward-looking statements or the occurrence of
unanticipated events. Factors that may impact Chembio's
success are more fully disclosed in Chembio's most recent public
filings with the U.S. Securities and Exchange Commission.
Contacts:
Company
Susan Norcott
(631) 924-1135 Ext. 125
snorcott@chembio.com
Investor Relations
Vida Strategic Partners (investors)
Stephanie C. Diaz
(415) 675-7401
sdiaz@vidasp.com
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Apr 2023 to Apr 2024